Patients Needed For Non-Hodgkin's Lymphoma Study
INDIANAPOLIS - Indiana University Cancer Center is seeking participants for a clinical trial of a drug that cuts off the blood supply to tumors of some patients with non-Hodgkin's lymphoma.
The drug, Avastin (formerly known as anti-VEGF) has been shown to be effective in the treatment of colorectal cancer. The trial will test its effectiveness when combined with regular chemotherapy and Rituxan, a monoclonal antibody.
The Phase II study will enroll patient for six months. To be eligible, patients must have large B cell non-Hodgkin's lymphoma, not have started treatment for the disease and be at Stage 3/Stage 4 or bulky Stage 2.
Avastin, made by Genentech, is an anti-angiogenetic agent. Angiogenesis is the development of blood vessel to supply and nurture a cancerous tumor. By halting the supply of blood, research indicates the tumor dies.
For additional information or to enroll in the trial, call Jill Weisenbach at 317-278-0597.
For additional information on clinical trials available at IU School of Medicine, see http://medicine.iupui.edu/ctp/.
# # #
Media Contact: Mary Hardin
317-274-7722
mhardin@iupui.edu
INDIANA UNIVERSITY
SCHOOL OF MEDICINE
A STATEWIDE
RESOURCE
Phone
317 274 7722
Fax
317 278 8722